Biotechnology

18 April 2025 by Mathieu Klos

Samsung Bioepis, Janssen, Stelara, SPC waiver

Biosimilars

Janssen appeals to Supreme Court after Samsung Bioepis win in SPC waiver case

Samsung Bioepis has won the right to produce a biosimilar of Janssen's autoimmune disorder treatment in Europe for export outside the EU, despite vali ...

15 April 2025 by Mathieu Klos

Amgen, Repatha, Sanofi, Regeneron, Praluent, cholesterol-lowering drugs

Pharmaceuticals

EPO and UPC disagree on validity of Amgen's patent for cholesterol drug

The EPO Opposition Division has rejected a challenge by Sanofi and Regeneron against a key patent covering Amgen’s cholesterol-lowering drug Repatha. ...

9 April 2025 by Konstanze Richter

GlaxoSmithKline, GSK, Pfizer, RSV, vaccines

Vaccine technology

GSK and Pfizer reach licensing deal over RSV vaccine

The global battle between GlaxoSmithKline and Pfizer over several patents for RSV vaccines has come to an end. The dispute was settled where it began, ...

27 March 2025 by Mathieu Klos

Unified Patent Court

UPC infringement case can resume after EPO upholds 10x Genomics patent

The EPO Opposition Division has upheld 10x Genomics' important spatial profiling patent. The Munich local division can now resume the infringement pro ...

5 March 2025 by Mathieu Klos

Moderna, BioNTech, Pfizer, corona, COVID-19, vaccine, mRNA,

mRNA technology

Moderna and Freshfields triumph in Düsseldorf against BioNTech and Pfizer

BioNTech and Pfizer must pay damages to Moderna for the use of one of its patents in Germany. This was the ruling handed down today by Düsseldorf Regi ...

Casalonga, Denise Nestle-Nguyen, Munich, Stolmàr & Partner

18 February 2025 by Mathieu Klos

Casalonga strengthens Munich office with Stolmár partner

Patent attorney Denise Nestle-Nguyen has joined Casalonga as partner in the Munich office. The move is part of a greater expansion of the firm in Euro ...

7 February 2025 by Konstanze Richter

Promosome, BioNTech, Pfizer, COVID-19, Comirnaty

mRNA technology

Battle over COVID-19 vaccines reaches UPC as Promosome sues BioNTech

The dispute over mRNA technology has now reached the UPC. After BioNTech's COVID-19 vaccine Comirnaty was attacked in national courts by Moderna and C ...

5 February 2025 by Mathieu Klos

Celltrion, Novartis, Genentech, Xolair, UK, biosimilar

Biosimilars

Bristows successful for Novartis against Celltrion's UK invalidity claim over Xolair

In the dispute with Celltrion over the asthma drug omalizumab, the UK High Court has ruled in favour of Novartis and Genentech. The two patent holders ...

df-mp Dörries Frank-Molnia & Pohlman, litigation, UPC

4 February 2025 by Konstanze Richter

df-mp hones structure to focus entirely on litigation

With a new firm structure and a focus on life sciences and hi-tech, the IP firm df-mp is concentrating entirely on patent litigation and strengthening ...

Claudia Hertzsch, Hoyng ROKH Monegier, König Szynka, Hoffmann Eitle, Düsseldorf

28 January 2025 by Mathieu Klos

Hoyng ROKH expands patent attorney practice with König Szynka partner

Claudia Hertzsch joins Hoyng ROKH Monegier on 1 April, where she will continue to focus on patent litigation. Her previous firm König Szynka Tilmann v ...

Hoffmann Eitle, König Szynka, Smorodin, Düsseldorf, Munich

14 January 2025 by Mathieu Klos

Hoffmann Eitle and König Szynka unite top pharma teams

A new heavyweight in the life sciences sector is emerging in Germany. The Düsseldorf team of König Szynka Tilmann von Renesse is to join Hoffmann Eitl ...

28 November 2024 by Mathieu Klos

CRISPR/Cas

Swerving the matter of granting genetic scissor patents at the EPO

This autumn, the EPO Boards of Appeal were supposed to issue landmark decisions in the battle for the basic patents on CRISPR/Cas9 technology. But the ...

Should pharma and biotech companies now be embracing the UPC?

Should pharma and biotech companies now be embracing the UPC? At this joint event hosted by Pinsent Masons and JUVE Patent, a group of industry lea ...

25 November 2024 by JUVE